**Proteins** 

# **Product** Data Sheet

## NC-III-49-1


Cat. No.: HY-150683 Molecular Formula:  $C_{44}H_{50}N_4O_{11}S_2$ Molecular Weight: 875.02

**Epigenetic Reader Domain** Target:

Pathway: **Epigenetics** 

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



## **BIOLOGICAL ACTIVITY**

Description NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. NC-III-49-1 shows binding potential

for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with K<sub>d</sub> values of 0.095, 0.32, 0.29, 0.089, 5.5, 0.058 nM, respectively.

 ${\sf NC-III-49-1}\ shows\ antiproliferative\ activity.\ NC-III-49-1\ decreases\ the\ expression\ of\ c-Myc^{[1]}.$ 

IC<sub>50</sub> & Target BRD4-1 BRD4-2 BRD4-T BRDT-1

> 0.095 nM (Kd) 0.032 nM (Kd) 0.29 nM (Kd) 0.089 nM (Kd)

BRDT-2 BRDT-T 5.5 nM (Kd) 0.058 nM (Kd)

In Vitro NC-III-49-1 (0-10  $\mu$ M; 72 h) shows antiproliferative activity with an IC<sub>50</sub> value of 0.69 nM in MM1.S cells<sup>[1]</sup>.

NC-III-49-1 (0-10  $\mu$ M; 6 h) decreases the expression of c-Myc in a dose dependent manner<sup>[1]</sup>.

.NC-III-49-1 shows inhibition by interact with both KAc sites<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[1]</sup>

Cell Line:	MM1.S cells
Concentration:	0-10 μΜ
Incubation Time:	72 h
Result:	Showed subnanomolar growth inhibition with an IC $_{\rm 50}$ value of 0.69 nM in multiple myeloma MM1.S cells.

## Western Blot Analysis<sup>[1]</sup>

Cell Line:	MM1.S cells
Concentration:	0-10 μΜ
Incubation Time:	6 h
Result:	Decreased the expression of c-Myc in a dose dependent manner.

#### In Vivo

NC-III-49-1 shows metabolic stability in human and mouse liver microsomes with an  $T_{1/2}$  values of <2.3, <2.3 min, respectively<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Guan X, et al. Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity. J Med Chem. 2022 Jul 22.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA